CDT Equity (CDT) Restructuring Costs (2024 - 2025)
CDT Equity's (CDT) quarterly Restructuring Costs came in at $1.0 million in Q3 2025, up 2.9% YoY from $999000.0 in Q3 2024, and down 5.77% on a QoQ basis from $1.1 million in Q2 2025.
CDT Equity (CDT) Restructuring Costs (2024 - 2025) Analysis & Trends
CDT Equity (CDT) has 2 years of Restructuring Costs data on file, last reported at $1.0 million in Q3 2025.
- Quarterly Restructuring Costs rose 2.9% year-over-year to $1.0 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $4.0 million (changed N/A YoY) and the FY2024 annual result came in at $4.1 million, up 278.38% from the prior year.
- Restructuring Costs retreated to $1.0 million in Q3 2025, from $1.1 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $1.1 million in Q4 2024 to a low of $703000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | CDT Equity | 1.59 Mn | 1.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 703,000.00 |
| Dec 31, 2024 | 1.15 Mn |
| Sep 30, 2024 | 999,000.00 |
| Jun 30, 2024 | 964,000.00 |
| Mar 31, 2024 | 949,000.00 |